Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Foretinib |
Trade Name | |
Synonyms | GSK1363089G|XL880|EXEL-2880 |
Drug Descriptions |
Foretinib (GSK1363089) is a multi-kinase inhibitor with activity against several receptor tyrosine kinases, including MET, KDR (VEGFR2), as well as ROS1 and NTRK fusions, which may result in decreased tumor angiogenesis and growth (PMID: 19808973, PMID: 26372962, PMID: 29463555, PMID: 30501104). |
DrugClasses | MET Inhibitor 59 ROS1 Inhibitor 22 TrkA Receptor Inhibitor 8 TYRO3 Inhibitor 7 VEGFR2 Inhibitor 37 |
CAS Registry Number | 849217-64-7 |
NCIT ID | C80058 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Foretinib | Foretinib | 15 | 0 |
Foretinib + PLX4720 | Foretinib PLX4720 | 0 | 0 |
Foretinib + Rucaparib | Foretinib Rucaparib | 0 | 0 |
Foretinib + Veliparib | Foretinib Veliparib | 0 | 0 |